Menu Back toS09-What-is-Shared-Value-Created-by-Collaboration-Among-Industry-Academia-Government-and-Individuals-of-Current-and-Future-Generations-Going-Forward-to-New-Era-of-Innovation

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S09] What is “Shared Value” Created by Collaboration Among Industry, Academia, Government and Individuals of Current and Future Generations - Going Forward to New Era of Innovation

Session Chair(s)

Minori  Niso

Minori Niso

  • Associate Brand Marketing Director, APAC Marketing
  • PAREXEL International Inc., Japan
With a decrease in the success probability of drug/device development, an idea of “open innovation” has been spreading out with a transition from a classical methodology to a brand new one by crossing organizational boundaries. In this session, with a theme of “Win-win relationship by industry, government and academia”, an example of government effort to connect industry and academia, and an idea of “creating shared value (CSV)” by the industry to achieve a synergism between economic benefit and social value creation will be reviewed. From academia, an example of a cross-cultural collaboration will be explained. Through these discussions, let us think about “What is new innovation toward the common goal by industry, government and academia?” for the better collaboration for our future.


Tomonori  Shiokawa

Measures by AMED for Drug Discovery and Development Through all Japan Partnership

Tomonori Shiokawa

  • Manager, Department of Innovative Drug Discovery and Development
  • Japan Agency for Medical Research and Development (AMED), Japan
Keiichi  Fujiwara, MD, PhD

Keiichi Fujiwara, MD, PhD

  • Professor, Department of Gynecologic Oncology Chief
  • Saitama Medical University International Medical Center, Japan
Ryota  Inaba

Overview of SDGs, CSV (Creating Shared Value) and Collective Impact

Ryota Inaba

  • General Manager
  • Flexas Z inc., Japan